CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last week for its ATR kinase inhibitor. As he describes, patient selection for these therapies can make a big difference.
View all episodes
By BiotechTV
4.3
66 ratings
CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last week for its ATR kinase inhibitor. As he describes, patient selection for these therapies can make a big difference.
3,223 Listeners
1,917 Listeners
124 Listeners
325 Listeners
61 Listeners
9,948 Listeners
86 Listeners
33 Listeners
353 Listeners
19 Listeners
60 Listeners
510 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
48 Listeners